Pharmafile Logo

Understanding the Patient Journey

July 6, 2016 | Patient journey, market research 


The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme.  Technology is changing the way that healthcare is delivered and the way that patients experience healthcare. The journey is also more complex, with increasing number of healthcare professionals having to work together to provide care.

http://www.researchpartnership.com/news/2016/06/news-understanding-the-patient-journey/

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

12 Challenges Big Pharma Faces in China

Published in eyeforpharma 16 November by Rachel Howard

Using mobile “diary” research to capture patient-generated insights in COPD

Our latest case study demonstrates how a mobile app methodology was used to deliver key insights into issues faced by COPD patients

Biosimilars in 2018: EU doctors’ perceptions of RA drug market

Published in pharmaphorum October 2015 by Laurent Chanroux

Webinar: Understanding the Patient Journey in China 2015

Utilising local knowledge and detailed case studies, this webinar examines the likely impact on the patient journey and consider the possible implications for market researchers.

Understanding Patient Willingness to Pay

Published in eyeforpharma 12 October by Rachel Howard

Infographic: Spondyloarthritis

Overview of spondyloarthritis patient profiles and treatment pathways.

Webinar: Demand assessment – Reflecting real world choices

How study design which reflects doctors’ real world choices can optimise results.

Evaluating the potential of a pre-launch prodct in a real-life setting

Using in-depth-interviews as well as a SmartPhone app to collect real patient cases from physicians to find out opportunity for a new product.

Competition from within

Published in eyeforpharma July 29 by Rachel Howard

Infographic: RA Perceptions

HCPs predict the future of the biologics market